BillionToOne, Inc. (BLLN) company profile
Close on Nov 17, 2026Market cap $4.60BP/E –Yield –
About BillionToOne
Services-Medical Laboratories, SIC 8071
BillionToOne, Inc. operates as a precision molecular diagnostics company specializing in non-invasive single-molecule next-generation sequencing tests. The organization develops liquid biopsy screening tools utilizing cell-free DNA to assess fetal genetic conditions and evaluate oncology therapy outcomes. Its prenatal portfolio includes the UNITY suite of maternal blood tests, which screen for recessive genetic conditions, chromosomal aneuploidies, microdeletions, and fetal red blood cell antigens. In oncology, the firm offers Northstar Select for solid tumor therapy guidance and Northstar Response for monitoring treatment efficacy and quantifying tumor burden. The company's primary customers include obstetricians, maternal-fetal medicine specialists, oncologists, healthcare systems, and clinical trial partners.
The business delivers its diagnostic screening services across the United States and has secured regulatory clearances for clinical trial testing in select European and Latin American jurisdictions. BillionToOne conducts prospective multi-site clinical evaluations across academic medical centers and healthcare networks, including over 150,000 completed fetal RhD assessments. The provided text does not identify the location of the company's headquarters.
Summary of the business section of BillionToOne's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BillionToOne, Inc.
- Founded
- 2016
- Headquarters
- Menlo Park, CA
- Address
- 1035 O'Brien Drive
- Phone
- (650) 460-2551
- Website
- billiontoone.com
- Employees
- 713, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- BLLN
- Exchange
- Nasdaq
- IPO date
- Nov 6, 2025
- Shares outstanding
- 47M, Aug 3, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 2070849
- CUSIP
- 090168105
- ISIN
- US0901681058
- FIGI
- BBG00NR7JXT0
- Share class FIGI
- BBG00NR7JXV7
- EIN
- 81-1082020
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Tsao | Chief Technology Officer, Director | 2,306,108 |
| Oguzhan Atay | Chairman and CEO, Director | 2,601,143 |
| Bosch John Roderick ten | SVP of Laboratory Operations | 16,551 |
| Thomas P. Lynch | See Remarks | 10,700 |
| Shan Riku Sakakibara | Chief Product Officer | 196,500 |
| Nancy JoAnn Johnson | See Remarks | 18,966 |
| John Lister | Chief Administrative Officer | – |
| Ross Taylor | Chief Financial Officer | – |
| Krishna Kittu Kolluri | Director | 1,646,225 |
| Firat Ileri | Director | 3,298,769 |
| Akshay Rai | Director | 3,582,854 |
| Anthony Pagano | Director | 7,913 |
| Thomas S. Bremner | Director | 1,161,734 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Oguzhan Atay Chief Executive Officer | $371.81K | $136.00K | $19.17M | $10.59K | $19.68M | +5205% |
| David Tsao President and Chief Technology Officer | $332.94K | $113.85K | $9.58M | $14.00K | $10.04M | +2632% |
| John Lister Chief Administrative Officer | $182.98K | $61.21K | $3.09M | $2.40K | $3.36M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 6, 2025
- Offer price
- $60.00
- Securities offered
- 4,551,100
- Gross proceeds
- $273.07M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- May 5, 2026
“The initial public offering price is $60.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 6, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 3, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?